Effects of ebselen and probucol on oxidative modifications of lipid and protein of low density lipoprotein induced by free radicals.
The oxidative modification of low density lipoprotein (LDL) is accepted to be an important early event of atherosclerosis, but it has not yet been well understood. The preventive effects of two antioxidants with different functions, ebselen and probucol, against the oxidative modification of LDL induced by copper or a water-soluble radical initiator, 2,2'-azobis(2-amidinopropane) dihydrochloride (AAPH) were studied in order to elucidate the mechanism of modification of apolipoprotein B-100 (apoB). Ebselen inhibited the copper-induced oxidation completely by reducing the hydroperoxides in LDL, since the initiation of copper-dependent oxidation requires the presence of a trace amount of hydroperoxides in LDL. On the other hand, ebselen did not suppress the oxidations of LDL induced by AAPH which generated free radicals by its thermal decomposition. The AAPH-induced oxidation of LDL in the absence of ebselen gave phosphatidylcholine hydroperoxide and cholesteryl ester hydroperoxide as major products, while in its presence, the hydroperoxides were reduced to corresponding alcohols. Interestingly, ebselen had little effect on the increase of relative electrophoretic mobility and fragmentation of intact apoB in the AAPH-induced oxidation. Probucol inhibited the oxidation of lipids in LDL effectively induced by either copper or AAPH, but the protein modifications were observed even in the presence of probucol. It was suggested that (1) lipid hydroperoxides do not play an important role in the modification of apoB such as increase in negative charge and fragmentation, (2) the direct attack of free radicals upon apoB and its modification by lipid oxidation products derived from hydroperoxides increase the negative charge of apoB, and (3) its fragmentation is caused primarily by an attack of free radicals.
Noguchi
N
N
Research Center for Advanced Science and Technology, University of Tokyo, Japan.
Gotoh
N
N
Niki
E
E
D000578:Amidines / Q000494:pharmacology; D000975:Antioxidants / Q000494:pharmacology*; D001055:Apolipoproteins B / Q000187:drug effects / Q000378:metabolism; D001161:Arteriosclerosis / Q000378:metabolism; D001393:Azoles / Q000494:pharmacology*; D003300:Copper / Q000494:pharmacology; D005609:Free Radicals; D006801:Humans; D066298:In Vitro Techniques; D054833:Isoindoles; D008077:Lipoproteins, LDL / Q000187:drug effects* / Q000378:metabolism*; D016566:Organoselenium Compounds / Q000494:pharmacology*; D010084:Oxidation-Reduction / Q000187:drug effects; D011341:Probucol / Q000494:pharmacology*
D000578:Amidines; D000975:Antioxidants; D001055:Apolipoproteins B; D001393:Azoles; D005609:Free Radicals; D054833:Isoindoles; D008077:Lipoproteins, LDL; D016566:Organoselenium Compounds; C042986:ebselen; C046728:2,2'-azobis(2-amidinopropane); D003300:Copper; D011341:Probucol